AI assistant
DEXCOM INC — Director's Dealing 2021
Dec 17, 2021
30198_dirs_2021-12-17_4a5da124-5314-40dc-a47c-50a1a41f0d51.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2021-12-15
Reporting Person: Stern Sadie (EVP Chief Human Resources Off)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-15 | Common Stock | A | 1671 | $0.001 | Acquired | 13461 | Direct |
Footnotes
F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.
F2: Included in this number are 13,461 unvested restricted stock units, 1,671 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, and 6,156 of which were granted on November 19, 2020 and shall vest through November 19, 2024.